CommentDiabetic kidney disease 2.0: the treatment paradigm shifts
References (10)
- et al.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Lancet
(2019) - et al.
A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury
Am J Kidney Dis
(2015) - et al.
Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis
Kidney Int
(2012) - et al.
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
N Engl J Med
(2016) - et al.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
N Engl J Med
(2019)
There are more references available in the full text version of this article.
Cited by (5)
Effect of Buyang Huanwutang on Ferroptosis in Diabetic Kidney Disease Mice
2023, Chinese Journal of Experimental Traditional Medical FormulaePediatric Diabetic Nephropathy: Novel Insights from microRNAs
2023, Journal of Clinical MedicineDanggui Buxuetang Alleviates Oxidative Stress and Inflammation in Diabetic Kidney Disease Rats by Improving Mitochondrial Dysfunction of Podocytes
2022, Chinese Journal of Experimental Traditional Medical FormulaeEffect of Danggui Buxuetang on Podocyte Injury in Diabetic Kidney Disease Rats: An Exploration Based on RIPK1/RIPK3/MLKL Signaling Pathway
2022, Chinese Journal of Experimental Traditional Medical FormulaeDapagliflozin Reduces Urinary Albumin Excretion by Downregulating the Expression of cAMP, MAPK, and cGMP-PKG Signaling Pathways Associated Genes
2021, Genetic Testing and Molecular Biomarkers
© 2019 Elsevier Ltd. All rights reserved.